23andme Holding CO 8-K filings

23andMe has entered into a consulting agreement with its former Chief Administrative Officer, Kathy Hibbs, following her retirement, to provide advisory services for a maximum of ten hours per month.

23andMe's fiscal year 2024 results show a substantial decrease in revenue and a significant increase in net losses, primarily due to the end of a key collaboration and lower sales.

23andMe has been granted a 180-day extension, until November 4, 2024, to regain compliance with Nasdaq's minimum bid price requirement, and its stock will move to the Nasdaq Capital Market on May 13, 2024.

23andMe's CEO, Anne Wojcicki, is exploring a potential take-private transaction, prompting the company's special committee to review strategic alternatives.

23andMe's Chief Administrative Officer, Kathy Hibbs, will retire effective May 24, 2024, and the company has appointed Guy Chayoun as the new Corporate Secretary.

23andMe's Q3 fiscal year 2024 results show a significant revenue decrease of 33% year-over-year, alongside a large net loss, prompting an adjustment to the company's full-year financial guidance.

23andMe has received FDA clearance for its investigational new drug application for 23ME-01473, a novel cancer therapy, and plans to begin Phase 1 clinical trials in the first half of 2024.